Trial Profile
A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha V beta 3 integrin, ± dacarbazine in patients with metastatic melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Etaracizumab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- 27 Jan 2010 Primary endpoint 'Time to disease progression' has not been met.
- 27 Jan 2010 Primary endpoint 'Objective clinical response rate' has not been met.
- 27 Jan 2010 Primary endpoint 'Disease progression rate' has not been met.